Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of APOL1-mediated kidney disease
Economic burden and healthcare resource utilization
8 evidence topics · 7 sources
AMKD-specific health care resource utilization and cost studies
No evidence found.
Treatment use among 1332 patients with genetically confirmed AMKD in the United States: conference poster report
Medicare expenditures for people with kidney failure
Medicare fee-for-service expenditures for people with CKD
Health care resource utilization and costs in 844 patients with FSGS and matched controls
“Patients with FSGS (n = 844; first claim = index event) between April 2016 and December 2018 were matched on index date, age, sex, and race to non-FSGS controls (n = 1688).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean total medical costs were higher in FSGS ($59,753 vs. $8431 PPPY; P < 0.0001), driven by outpatient costs. Nephrotic range proteinuria was associated with higher all-cause inpatient, outpatient, and prescription costs versus nonnephrotic patients (all P < 0.0001), resulting in higher total costs ($70,481 vs. $36,099 PPPY; P < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource utilization and costs in FSGS by proteinuria and CKD stage: 9899 patients in a US claims and EHR database
“In this descriptive, noninterventional, retrospective cohort study, 9899 patients were identified between January 2016 and December 2020 in Optum de-identified Market Clarity Data” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“There was a consistent trend toward higher health care resource utilization and total costs with both chronic kidney disease progression (stage 1-5/kidney failure) and higher levels of proteinuria” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The observed prevalence of FSGS increased in the US and was highest among Black individuals. More advanced chronic kidney disease and higher levels of proteinuria were both associated with greater health care resource utilization and costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource utilization and costs in FSGS-attributed kidney failure
“The FSGS cohort and Medicare Coverage and 1-year Medicare Coverage subgroups included 25,699, 6,340, and 5,575 patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Medicare Coverage and 1-year Medicare Coverage subgroups, 76.6% and 74.2% required inpatient admission, 69.9% and 67.3% visited the emergency room, and mean monthly health care costs were $6,752 and $5,575 in the year postindex, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug costs may be underestimated because Medicare Part D coverage was not required; kidney acquisition costs were not available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource utilization and costs in 2515 US veterans with FSGS
“The study included 2,515 veterans with FSGS who were followed for an average of 8.9 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 43.3% underwent dialysis and 5.8% had a kidney transplant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“During the first year post-index, 40% had an inpatient admission and 33% visited the emergency room; mean total healthcare cost per patient in the analysis was $36,543.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote